Key Takeaways from JACC: (February 5th 2025 ) Beta-Blockers and Broken heart syndrome “Takotsubo Syndrome(TTS)”
Key Takeaways from JACC: (February 5th 2025 ) Beta-Blockers and Broken heart syndrome “Takotsubo Syndrome(TTS)”:
• Beta-blockers significantly reduce long-term mortality in TTS patients, as shown in a large, multinational study.
• TTS (“broken heart syndrome”) is a rare but serious heart condition that mimics a heart attack and can lead to heart failure and arrhythmias.
• Study Details: Over 2,800 patients from Spain, Italy, and Germany (2002–2022), with 71% receiving beta-blockers at discharge.
• Results:
• Lower mortality rates in beta-blocker users (6 vs. 8.1 deaths per 100 patients/year).
• No impact on TTS recurrence or left ventricular function.
• Conclusion: Findings support the need for clinical trials to confirm the mortality benefit of beta-blockers in TTS.
https://www.jacc.org/doi/10.1016/j.jchf.2024.11.015
